Screener
Medtronic MDT Cardiovascular — Research and development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Medtronic’s 10-K, filed June 18, 2026.
- Filed
- Jun 18, 2026, 4:27 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-044354
| (in millions) | Cardiovascular | Neuroscience | Medical Surgical | Total |
|---|---|---|---|---|
| Total consolidated net sales | $36,364 | |||
| Less: | ||||
| Cost of products sold, excluding amortization of intangible assets | 4,695 | 3,151 | 3,476 | 11,323 |
| Research and development expense | 1,136 | 616 | 686 | 2,438 |
| Selling, general, and administrative expense | 4,519 | 3,421 | 2,511 | 10,451 |
| Other segment items(3) | (46) | 36 | 14 | 4 |
| Reportable segment operating profit | $3,672 | $3,062 | $2,128 | $8,862 |
| Reconciliation of segment profit / (loss) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Medtronic's cardiovascular — research and development expense?
- Medtronic (MDT) reported cardiovascular — research and development expense of $273M in Q1 2026.
- How has Medtronic's cardiovascular — research and development expense changed year-over-year?
- Medtronic's cardiovascular — research and development expense increased by 5.4% year-over-year, from $259M to $273M.
- What is the long-term trend for Medtronic's cardiovascular — research and development expense?
- Over 3 years (2023 to 2026), Medtronic's cardiovascular — research and development expense has grown at a 11.7% compound annual growth rate (CAGR), from $815M to $1.14B.
- What does cardiovascular — research and development expense mean?
- This represents the costs incurred by the cardiovascular business segment to research, design, and develop new medical devices and therapeutic technologies. It reflects the company's commitment to innovation and long-term pipeline growth within the heart and vascular health market. High investment levels are typically required to maintain a competitive edge in complex medical device markets.
Ask your AI about Medtronic's cardiovascular — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude